Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Characterization Of Circulating Tumor Cells By Fluorescence In Situ Hybridization

J. Swennenhuis, A. Tibbe, Rianne Levink, R. Sipkema, L. Terstappen
Published 2009 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Tumor cells in blood of patients with metastatic carcinomas have been associated with poor survival prospects. Further characterization of these cells may provide further insights into the metastatic process. Circulating Tumor Cells (CTC) were enumerated in 7.5 mL of blood with the CellSearch™ system. After enumeration of Cytokeratin+, CD45−, nucleated cells, the cells are fixed in the cartridge while maintaining their original position. Cartridges were hybridized with FISH probes against the centromeric regions of chromosome 1, 7, 8, and 17. Next fluorescence images of the FISH probes of the previous identified CTC were acquired. Leukocytes surrounding the CTC were used as internal controls. The number of copies of chromosome 1, 7, 8, and 17 could be determined in 118 CTC containing blood samples from 59 metastatic prostate cancer patients. The samples contained a total of 21,751 CTC (mean 184, median 16, SD 650). Chromosome counts were obtained in 61% of the relocated CTC. On an average, these CTC contained 2.8 copies of chromosome 1, 2.7 copies of chromosome 7, 3.1 copies of chromosome 8, and 2.3 copies of chromosome 17. CTC in which no chromosome count was obtained most likely underwent apoptosis indicated by the expression of M30. In 6/59 patients only diploid CTC were detected these samples, however, only contained 1–5 CTC. Heterogeneity in the chromosomal abnormalities was observed between CTC of different patients as well as among CTC of the same patient. Cytogenetic composition of CTC can be reliably assessed after they have been identified by the CellSearch™ system. The majority of CTC in hormone refractory prostate cancer are aneuploid confirming that they indeed are cancer cells. An extensive heterogeneity in the copy number of each of the chromosomes was observed. © 2009 International Society for Advancement of Cytometry
This paper references
10.1200/JCO.2005.08.140
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
M. Cristofanilli (2005)
10.1043/0003-9985(1999)123<0426:SCC>2.0.CO;2
Small cell carcinocythemia.
C. C. Sile (1999)
10.1073/PNAS.0402993101
HER-2 gene amplification can be acquired as breast cancer progresses.
S. Meng (2004)
10.1158/1078-0432.CCR-04-1110
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
S. Meng (2004)
A sample preparation and analysis system for identification of circulating tumor cells
M Kagan (2002)
10.1056/NEJMOA040766
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
M. Cristofanilli (2004)
Terstappen LWMM. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer
D F Hayes (2002)
10.3892/IJO.21.5.1111
Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.
D. Hayes (2002)
10.1002/cyto.a.20073
Apoptosis of circulating tumor cells in prostate cancer patients
Christopher J. Larson (2004)
10.1200/JCO.2007.13.6523
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.
K. Pachmann (2008)
10.1038/nature06385
Isolation of rare circulating tumour cells in cancer patients by microchip technology
S. Nagrath (2007)
10.1200/JCO.1992.10.8.1208
Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.
M. Ritter (1992)
10.1158/1078-0432.CCR-07-0268
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
J. D. de Bono (2007)
10.1016/0002-9343(76)90437-X
Carcinocythemia (carcinoma cell leukemia). An acute leukemia-like picture due to metastatic carcinoma cells.
R. W. Carey (1976)
10.1158/1078-0432.CCR-05-2821
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
D. Hayes (2006)
10.1056/NEJM198809013190901
Genetic alterations during colorectal-tumor development.
B. Vogelstein (1988)
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.
T. Fehm (2002)
Magnetic separation apparatus and methods
Terstappen LWMM (2003)
10.1002/1097-0142(20000615)88:12<2787::AID-CNCR18>3.0.CO;2-2
Identification and characterization of circulating prostate carcinoma cells
Z. Wang (2000)
10.1073/pnas.0608113103
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues
S. Meng (2006)
[Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation].
H. C. Engell (1955)
10.1093/JNCI/93.15.1141
Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.
R. Simon (2001)
10.1158/1078-0432.CCR-08-0872
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
J. D. de Bono (2008)
10.1385/EP:11:2:137
Genetic changes in chromosomes 1p and 17p in thyroid cancer progression
C. Kleer (2000)
10.1023/A:1011184706281
Carcinocythemia as the single extension of breast cancer: report of a case and review of the literature.
S. Séronie-Vivien (2001)
10.1200/JCO.2007.15.8923
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
S. Cohen (2008)
10.1158/1078-0432.CCR-04-0378
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
W. Allard (2004)
10.1038/bjc.1998.549
Sequential loss of heterozygosity in the progression of squamous cell carcinoma of the lung.
C. Endo (1998)
Circulating Tumor Cells (CTC) predict survival benefit from treatment in metastatic castration resistant prostate cancer (CRPC)
JS DeBono (2008)
Circulating tumor cells as cancer markers, a sample preparation and analysis system
M Kagan (2002)
10.1006/SCBI.1999.0124
Molecular genetics of breast cancer progression.
Sigurður Ingvarsson (1999)
10.1016/J.CHROMA.2007.05.064
Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells.
Siyang Zheng (2007)
10.1002/CYTO.10060
Magnetic field design for selecting and aligning immunomagnetic labeled cells.
A. G. Tibbe (2002)
10.1002/1097-0142(19840301)53:5<1100::AID-CNCR2820530514>3.0.CO;2-K
Carcinocythemia (carcinoma cell leukemia). Report of two cases with english literature review
M. V. Gallivan (1984)
10.1158/1078-0432.CCR-05-1769
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
G. Budd (2006)
10.1109/IEMBS.2010.5627655
Lab-on-chip for the isolation and characterization of circulating tumor cells
T. Roeser (2007)
10.1369/jhc.2008.951111
Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques
M. Campos (2008)
10.1002/cyto.a.20369
Statistical considerations for enumeration of circulating tumor cells
A. Tibbe (2007)
10.1002/1097-0142(197712)40:6<3107::AID-CNCR2820400653>3.0.CO;2-5
Carcinocythemia (carcinoma cell leukemia) due to metastatic carcinoma of the breast. Report of a case
R. Myerowitz (1977)
Immunocytodiagnosis of carcinocythemia in disseminated breast cancer.
L. Yam (1987)
Targeted therapy for cancer: the HER-2/neu and Herceptin story.
J. Ross (2003)
Circulating tumor cells predict progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients
DF Hayes (2006)
10.1073/PNAS.95.8.4589
Detection and characterization of carcinoma cells in the blood.
E. Racila (1998)
Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression.
G. Pihan (2001)
Immunocytodiagnosis of carcinocythemia in disseminated breast cancer.
Yam Lt (1987)
10.1007/s10585-006-9052-8
Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value
S. Tveito (2006)
10.1021/ja8015022
Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor.
André A. Adams (2008)
A case of cancer in which cells similar to those in the tumours were seen in the blood after death
TR Ashworth (1869)
10.1200/jco.2004.22.14_suppl.9552
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases.
W. Allard (2004)
10.1038/labinvest.3780096
Identification of Genetic Markers for Prostatic Cancer Progression
J. Alers (2000)
10.1158/1078-0432.CCR-06-2701
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
D. Shaffer (2007)
10.1007/s10585-007-9137-z
Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen
C. Schindlbeck (2007)



This paper is referenced by
10.1016/B978-0-12-386456-7.07714-5
Circulating Tumor Cells as a Real-Time Liquid Biopsy: Isolation and Detection Systems, Molecular Characterization, and Clinical Applications
E. Lianidou (2014)
10.3390/cancers5041619
Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis
A. Barradas (2013)
10.1002/1878-0261.12537
Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA
J. Lee (2019)
10.1083/jcb.201010021
Circulating tumor cells: approaches to isolation and characterization
M. Yu (2011)
Metastasis and Circulating Tumor Cells
G. van Dalum (2012)
Detection and characterization of circulating tumor cells in patients with testicular germ cell tumors and prostate cancer
P. Nastały (2014)
10.1586/14737159.2016.1123095
Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution
N. Stoecklein (2016)
10.18632/oncotarget.14203
Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip
Wanlei Gao (2017)
10.1002/cyto.a.23684
CTC Technologies and Tools
F. Coumans (2018)
10.1080/14737159.2016.1255144
Improving the CellSearch® system
J. Swennenhuis (2016)
10.1158/1078-0432.CCR-12-1585
Challenges in the Enumeration and Phenotyping of CTC
F. Coumans (2012)
10.1177/1758834010378414
Circulating tumour cells: their utility in cancer management and predicting outcomes
M. Krebs (2010)
10.3390/diagnostics8020026
Aneuploid CTC and CEC
P. Lin (2018)
10.1002/9781119244554.CH19
CELLSEARCH® Instrument, Features, and Usage
Denis Smirnov (2016)
10.1371/journal.pone.0067148
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer
S. Ligthart (2013)
10.1002/ADFM.201504176
Magnetic‐Nanoparticle‐Based Immunoassays‐on‐Chip: Materials Synthesis, Surface Functionalization, and Cancer Cell Screening
Y. Zhu (2016)
10.1002/cyto.a.21025
Steps in metastasis research: Analyzing, collecting, and culturing circulating tumor cells
Márk Barok (2011)
10.1158/1078-0432.CCR-10-1449
M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis
E. Rossi (2010)
Application de la technique CellSearch® Veridex pour la détection de cellules tumorales dans les liquides biologiques chez les patients atteints de cancers
Qian Tu (2015)
10.1146/annurev-med-062310-094219
Circulating tumor cells and circulating tumor DNA.
C. Alix-Panabières (2012)
10.21236/ada596639
Single Cell Characterization of Prostate Cancer-Circulating Tumor Cells
J. B. Brooks (2011)
Turning over a New Leaf : precision medicine in oncology guided by circulating tumor cell counts and characteristics
Wendy Onstenk (2016)
10.1158/1078-0432.CCR-19-2541
Analysis of Released Circulating Tumor Cells During Surgery for Non-Small Cell Lung Cancer
M. Tamminga (2019)
10.1088/1361-6528/aa7f84
Functionalization of nanotextured substrates for enhanced identification of metastatic breast cancer cells.
Nuzhat Mansur (2017)
10.1093/jnci/dju066
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
B. Rack (2014)
10.1155/2014/819362
Detection of Circulating Tumor Cells
S. de Wit (2014)
10.6000/1929-2279.2015.04.01.2
Circulating Tumor Cells: A Window to Understand Cancer Metastasis, Monitor and Fight Against Cancers
L. Xu (2015)
10.1007/978-3-642-16483-5_1182
Circulating Tumor Cells.
B. Mostert (2016)
10.1038/srep15980
Heterogeneity of miR-10b expression in circulating tumor cells
Christin Gasch (2015)
10.1111/bjh.15003
Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders
Brad Foulk (2018)
1 Apoptotic Circulating Tumor Cells ( CTCs ) in early and metastatic breast cancer patients
G. Kallergi (2013)
10.1158/0008-5472.CAN-08-3667
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
G. Attard (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar